These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 16918957)

  • 1. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
    Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
    Kim TY; Kim WB; Song JY; Rhee YS; Gong G; Cho YM; Kim SY; Kim SC; Hong SJ; Shong YK
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):588-93. PubMed ID: 16268813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.
    Howell GM; Carty SE; Armstrong MJ; Lebeau SO; Hodak SP; Coyne C; Stang MT; McCoy KL; Nikiforova MN; Nikiforov YE; Yip L
    Ann Surg Oncol; 2011 Dec; 18(13):3566-71. PubMed ID: 21594703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients.
    Pelttari H; Schalin-Jäntti C; Arola J; Löyttyniemi E; Knuutila S; Välimäki MJ
    APMIS; 2012 May; 120(5):380-6. PubMed ID: 22515292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
    Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
    Cañadas Garre M; López de la Torre Casares M; Becerra Massare P; López Nevot MÁ; Villar Del Moral J; Muñoz Pérez N; Vílchez Joya R; Montes Ramírez R; Llamas Elvira JM
    Endocrinol Nutr; 2011 Apr; 58(4):175-84. PubMed ID: 21441079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas.
    Nakayama H; Yoshida A; Nakamura Y; Hayashi H; Miyagi Y; Wada N; Rino Y; Masuda M; Imada T
    Anticancer Res; 2007; 27(5B):3645-9. PubMed ID: 17972530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
    Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.
    Yip L; Nikiforova MN; Carty SE; Yim JH; Stang MT; Tublin MJ; Lebeau SO; Hodak SP; Ogilvie JB; Nikiforov YE
    Surgery; 2009 Dec; 146(6):1215-23. PubMed ID: 19958951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF(V600E) mutation and the biology of papillary thyroid cancer.
    Frasca F; Nucera C; Pellegriti G; Gangemi P; Attard M; Stella M; Loda M; Vella V; Giordano C; Trimarchi F; Mazzon E; Belfiore A; Vigneri R
    Endocr Relat Cancer; 2008 Mar; 15(1):191-205. PubMed ID: 18310287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma.
    Wang W; Zhao W; Wang H; Teng X; Wang H; Chen X; Li Z; Yu X; Fahey TJ; Teng L
    Ann Surg Oncol; 2012 Jan; 19(1):31-6. PubMed ID: 22033631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
    Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
    Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR.
    Jeong D; Jeong Y; Park JH; Han SW; Kim SY; Kim YJ; Kim SJ; Hwangbo Y; Park S; Cho HD; Oh MH; Yang SH; Kim CJ
    Ann Surg Oncol; 2013 Mar; 20(3):759-66. PubMed ID: 23179992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of BRAF V600E mutation in different thyroid lesions].
    Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.
    Howell GM; Nikiforova MN; Carty SE; Armstrong MJ; Hodak SP; Stang MT; McCoy KL; Nikiforov YE; Yip L
    Ann Surg Oncol; 2013 Jan; 20(1):47-52. PubMed ID: 22941165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
    Walczyk A; Kowalska A; Kowalik A; Sygut J; Wypiórkiewicz E; Chodurska R; Pięciak L; Góźdź S
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):899-904. PubMed ID: 24354346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [BRAF V600E mutation in papillary thyroid carcinoma: prevalence and detection in fine needle aspiration specimens].
    Dujardin F; Pagès JC; Collin C; de Calan L; Lecomte P; Guyétant S
    Ann Pathol; 2010 Aug; 30(4):252-62. PubMed ID: 20837233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.
    Oler G; Cerutti JM
    Cancer; 2009 Mar; 115(5):972-80. PubMed ID: 19152441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
    Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R
    Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.